Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2016 | Pages:
73 | Publisher: Grand View Research
Industry: Pharmaceutical | Report Format: Electronic (PDF)
The global alzheimer's therapeutics market is expected to reach USD 6.4 billion in 2024, according to a new report by Grand View Research. Some primary factors driving the market growth includes rising government initiatives in order to raise awareness levels among people. Growing knowledge about the Alzheimer's disease (AD) and its high prevalence and incidence in developing economies are few of the major drivers supporting the market growth. Several governments, nonprofit, and private organizations worldwide are actively engaged in increasing people's awareness regarding progressive AD, such as Alzheimer's Association, the Alzheimer's Society of Canada, Alzheimer's Europe organization, and various other small organizations. Furthermore, the increased government funding for providing better care and support to the people with partial dementia is another important factor anticipated to enlarge market growth. For instance, organizations like Florida Department of Health, the National Institute of Health, and Alzheimer's Association in partnership with other private and government organizations provide funds to the research centers. The presence of various pipeline drugs is anticipated to provide the market with potential growth opportunities. For instance, LMTX by TauRx Pharmaceutical Ltd.; idalopirdine (Lu AE58054) by Lundbeck; crenezumab by AC Immune SA; and BAN2401 by Eisai Moreover, novel therapeutics with minimal dosage requirement has been introduced resulting in cost-effective alternatives, which is further expected to boost the market growth. For instance, Namzaric by Actavis was developed in two forms: 10 mg and 28 mg. 10 mg requires to be administered twice a day, while 28 mg requires to be administered once in a day. Further key findings from the study suggest: The cholinesterase inhibitors segment was dominant in 2013 but lost hold on the market till 2015. Patent expiry of key drugs such as Aricept, Exelon, and Razadyne was the major factor for decline in market share. Exelon transdermal patch is estimated to lose exclusivity in 2019. It is a highly prescribed drug for the treatment of mild to moderate AD, which contributed toward its revenue generation in 2015. N-methyl-D-aspartate receptor antagonist, on the other hand, is expected to witness a significant growth of around 16.0% over the forecast period owing to introduction of extended relase formulation of Namenda. Other drug therapies such as monocloclonal antibodies and drugs targeting Tau proteins are in being studied in latter phases of the clinical trials. Presence of a strong of pipeline drugs for target disease are attributing toward fastest growth of these drugs North America dominated the overall market in terms of revenue with share of over 33.0% in 2015, which is majorly facilitated by the availability of sophisticated healthcare facilities and infrastructure. Some key players operating in this industry are Pfizer, Inc.; Merck & Co. Inc.; Novartis AG; Eisai Co. Ltd., H. Lundbeck A/S, AC Immune; TauRx Pharmaceuticals Ltd.; Actavis plc.; Forest Laboratories; and Teva Pharmaceuticals Industries Ltd. Market players are expanding their product portfolio by developing and launching generic versions of drugs to sustain its market position. For instance, in 2015, Dr. Reddy's Laboratories Ltd. and Mylan launched the generic version of Namenda (Forest laboratories - Actavis).
Table of Contents
Chapter 1 Executive Summary Chapter 2 Market Snapshot Chapter 3 Industry Outlook 3.1 Market Segmentation & Scope 3.2 Market Size and Growth Prospects 3.2.1 Market driver analysis 3.2.1.1 Increasing prevalence of Alzheimer's disease 3.2.1.2 Introduction of new and innovative technologies and drugs 3.2.1.3 Increased government funding 3.2.1.4 Awareness programs 3.2.2 Market restraint analysis 3.2.3 Alzheimer's therapeutics market - Key market restraint analysis 3.2.3.1 Presence of stringent regulatory framework and long approval time for Alzheimer's therapeutics 3.2.4 Alzheimer's therapeutics Market dynamics 3.2.5 Key opportunities prioritized 3.2.6 Industry analysis - Porter's 3.2.7 Alzheimer's therapeutics - PESTEL analysis Chapter 4 Market Categorization 1: Product Estimates & Trend Analysis 4.1 Alzheimer's therapeutics market share by drug class, 2015 & 2024 4.2 Cholinesterase inhibitors 4.2.1 Cholinesterase inhibitor market estimates, 2013 - 2024 (USD Million) 4.3 N-Methyl-D-Aspartate (NMDA) Receptor Antagonist 4.3.1 NMDA receptor antagonist market estimates, 2013 - 2024 (USD Million) Chapter 5 Alzheimer's Market Categorization 2: Regional Estimates & Trend Analysis, by Product 5.1 Alzheimer's Therapeutics Market Share by Region, 2015& 2024 5.2 North America 5.2.1 North America Alzheimer's therapeutics market, 2013 - 2024 (USD Million) 5.2.2 U.S 5.2.2.1 U.S. Alzheimer's therapeutics market, 2013 - 2024 (USD Million) 5.2.3 Canada 5.2.3.1 Canada Alzheimer's therapeutics market, 2013 - 2024 (USD Million) 5.3 Europe 5.3.1 Europe Alzheimer's therapeutics market, 2013 - 2024 (USD Million) 5.3.2 UK 5.3.2.1 UK Alzheimer's therapeutics market, 2013 - 2024 (USD Million) 5.3.3 Germany 5.3.3.1 Germany Alzheimer's therapeutics market, 2013 - 2024 (USD Million) 5.4 Asia Pacific 5.4.1 Asia Pacific Alzheimer's therapeutics market, 2013 - 2024 (USD Million) 5.4.2 China 5.4.2.1 China Alzheimer's therapeutics market, 2013 - 2024 (USD Million) 5.4.3 Japan 5.4.3.1 Japan Alzheimer's therapeutics market, 2013 - 2024 (USD Million) 5.5 Latin America 5.5.1 Latin America Alzheimer's therapeutics market, 2013 - 2024 (USD Million) 5.5.2 Brazil 5.5.2.1 Brazil Alzheimer's therapeutics market, 2013 - 2024 (USD Million) 5.5.3 Mexico 5.5.3.1 Mexico Alzheimer's therapeutics market, 2013-2024 (USD Million) 5.6 MEA 5.6.1 MEA Alzheimer's therapeutics market, 2013-2024 (USD Million) 5.6.2 South Africa 5.6.2.1 South Africa Alzheimer's therapeutics market, 2013 - 2024 (USD Million) Chapter 6 Competitive Landscape 6.1 Pfizer, Inc. 6.1.1 Company overview 6.1.2 Financial performance 6.1.3 Product benchmarking 6.1.4 Strategic initiatives 6.2 Eisai Co. Ltd. 6.2.1 Company overview 6.2.2 Financial performance 6.2.3 Product benchmarking 6.2.4 Strategic initiatives 6.3 Actavis + Forest Laboratories 6.3.1 Company overview 6.3.2 Financial performance 6.3.3 Product benchmarking 6.3.4 Strategic initiatives 6.4 Lundbeck A/S 6.4.1 Company overview 6.4.2 Financial performance 6.4.3 Product benchmarking 6.4.4 Strategic initiatives 6.5 AC Immune 6.5.1 Company overview 6.5.2 Financial performance 6.5.3 Product benchmarking 6.5.4 Strategic initiatives 6.6 Merck KGaA 6.6.1 Company overview 6.6.2 Financial performance 6.6.3 Product benchmarking 6.6.4 Strategic initiatives 6.7 Novartis AG. 6.7.1 Company overview 6.7.2 Financial performance 6.7.3 Product benchmarking 6.7.4 Strategic initiatives 6.8 TauRx Pharmaceuticals Ltd. 6.8.1 Company overview 6.8.2 Financial performance 6.8.3 Product benchmarking 6.8.4 Strategic initiatives
List of Tables
TABLE 1 Alzheimer's therapeutics market - Key market driver analysis TABLE 2 Cholinesterase inhibitor market: Drug overview TABLE 3 N-methyl-D-aspartate receptor antagonist market: Drug overview TABLE 4 North America Alzheimer's therapeutics market estimates, by drug class, 2013 - 2024 (USD Million) TABLE 5 U.S. Alzheimer's therapeutics market estimates, by drug class, 2013 - 2024 (USD Million) TABLE 6 Canada Alzheimer's therapeutics market estimates, by drug class, 2013 - 2024 (USD Million) TABLE 7 Europe Alzheimer's therapeutics market estimates, by drug class, 2013 - 2024 (USD Million) TABLE 8 UK Alzheimer's therapeutics market estimates, by drug class, 2013 - 2024 (USD Million) TABLE 9 Germany Alzheimer's therapeutics market estimates, by drug class, 2013 - 2024 (USD Million) TABLE 10 Asia Pacific Alzheimer's therapeutics market estimates, by drug class, 2013 - 2024 (USD Million) TABLE 11 China Alzheimer's therapeutics market estimates, by drug class, 2013 - 2024 (USD Million) TABLE 12 Japan Alzheimer's therapeutics market estimates, by drug class, 2013 - 2024 (USD Million) TABLE 13 Latin America Alzheimer's therapeutics market estimates, by drug class, 2013 - 2024 (USD Million) TABLE 14 Brazil Alzheimer's therapeutics market estimates, by drug class, 2013 - 2024 (USD Million) TABLE 15 Mexico Alzheimer's therapeutics market estimates, by drug class, 2013 - 2024 (USD Million) TABLE 16 MEA Alzheimer's therapeutics market estimates, by drug class, 2013 - 2024 (USD Million) TABLE 17 South Africa Alzheimer's therapeutics market estimates, by drug class, 2013 - 2024 (USD Million)
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
